WYETH PHARMACEUTICALS INC.

Vima Therapeutics launched with $60 million Series A funding led by Atlas Venture to advance VIM0423, a potential first-in-class oral therapy for dystonia targeting muscarinic cholinergic receptors.

SK Bioscience has successfully won an appeal against Pfizer's subsidiary Wyeth LLC in a patent dispute over pneumococcal vaccine components exported to Russia for research purposes.

WuXi PharmaTech has appointed several key executives to its Board of Directors, including Ying Han, Stewart Hen, and co-founder Ning Zhao, bringing valuable financial and pharmaceutical expertise to the company.